Press release
Pheochromocytoma Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | Pfizer, Exelixis, Ipsen, Genentech, and others.
Pheochromocytoma Pipeline
In the Pheochromocytoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Pheochromocytoma clinical trials studies, Pheochromocytoma NDA approvals (if any), and product development activities comprising the technology, Pheochromocytoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Pheochromocytoma Pipeline Report
• DelveInsight's Pheochromocytoma Pipeline analysis depicts a robust space with 8+ active players working to develop 8+ pipeline treatment therapies.
• The leading Pheochromocytoma Companies include Pfizer, Exelixis, Ipsen, Genentech, Astex Pharmaceuticals, Advanced Accelerator Applications, and others.
• Promising Pheochromocytoma Pipeline Therapies include 123I-mIBG (meta-iodobenzylguanidine), Ultratrace Iobenguane (MIBG) I 131, Sunitinib, temsirolimus, vinorelbine ditartrate, isolated perfusion, melphalan, Indium-111 pentetreotide, and others.
• The Pheochromocytoma companies and academics are working to assess challenges and seek opportunities that could influence Pheochromocytoma R&D. The Pheochromocytoma pipeline therapies under development are focused on novel approaches to treat/improve Pheochromocytoma.
Request a sample and discover the recent breakthroughs happening in the Pheochromocytoma Pipeline landscape @ Pheochromocytoma Pipeline Outlook- https://www.delveinsight.com/report-store/pheochromocytoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Pheochromocytoma Overview
Pheochromocytoma is a rare tumor that usually starts in the cells of one of your adrenal glands. It results in the release of too much epinephrine and norepinephrine, hormones that control heart rate, metabolism, and blood pressure. Pheochromocytoma may occur as a single tumor or as more than one growth. It usually develops in the center (medulla) of one or both adrenal glands. Symptoms associated with pheochromocytomas include high blood pressure (hypertension), headaches, excessive sweating, and/or heart palpitations. In approximately 25 to 35 percent of cases, pheochromocytomas may be inherited as an autosomal dominant trait.
Pheochromocytoma Emerging Drugs Profile
• Sunitinib: Pfizer
Sunitinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. Sunitinib is approved in first-line treatment for patients with advanced renal cell carcinoma (RCC) and for the treatment of patients with gastrointestinal stromal tumors (GIST) after disease progression or intolerance to imatinib mesylate therapy. The drug is in Phase II clinical studies for the treatment of Pheochromocytoma.
• Guadecitabine: Astex Pharmaceuticals
Guadecitabine is a next-generation DNA hypomethylating agent. Guadecitabine is rationally designed to be resistant to degradation by cytidine deaminase, prolonging the exposure of tumor cells to the active metabolite, decitabine, thus ensuring greater uptake of decitabine into the DNA of rapidly dividing cancer cells. Guadecitabine-mediated inhibition of DNA methylation upregulates tumor-associated antigens and may sensitize tumor cells to other anticancer agents, including immunotherapeutics, as well as resensitize resistant cancer cells to chemotherapeutics. The drug is in Phase II clinical evaluation for the treatment of Pheochromocytoma.
For further information, refer to the detailed Pheochromocytoma Drugs Launch, Pheochromocytoma Developmental Activities, and Pheochromocytoma News, click here for Pheochromocytoma Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/pheochromocytoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Pheochromocytoma Pipeline Therapeutics Assessment
There are approx. 8+ key companies which are developing the therapies for Pheochromocytoma. The companies which have their Pheochromocytoma drug candidates in the most advanced stage, i.e. Preregistration include, Pfizer.
Pheochromocytoma Pipeline: Phases
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Find out more about the Pheochromocytoma Pipeline Segmentation, Therapeutics Assessment, and Pheochromocytoma Emerging Drugs @ Pheochromocytoma Treatment Landscape- https://www.delveinsight.com/sample-request/pheochromocytoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Pheochromocytoma Pipeline Report
• Coverage- Global
• Pheochromocytoma Companies- Pfizer, Exelixis, Ipsen, Genentech, Astex Pharmaceuticals, Advanced Accelerator Applications, and others.
• Pheochromocytoma Pipeline Therapies- 123I-mIBG (meta-iodobenzylguanidine), Ultratrace Iobenguane (MIBG) I 131, Sunitinib, temsirolimus, vinorelbine ditartrate, isolated perfusion, melphalan, Indium-111 pentetreotide, and others
• Pheochromocytoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for Pheochromocytoma Pipeline Companies and Therapies, click here @ Pheochromocytoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/pheochromocytoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Pheochromocytoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Pheochromocytoma - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Pheochromocytoma Collaboration Deals
9. Late Stage Products (Preregistration)
10. Drug name: Company name
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Sunitinib: Pfizer
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Drug name: Company name
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. Drug name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Pheochromocytoma Key Companies
23. Pheochromocytoma Key Products
24. Pheochromocytoma- Unmet Needs
25. Pheochromocytoma- Market Drivers and Barriers
26. Pheochromocytoma- Future Perspectives and Conclusion
27. Pheochromocytoma Analyst Views
28. Pheochromocytoma Key Companies
29. Appendix
Got Queries? Find out the related information on Pheochromocytoma Mergers and acquisitions, Pheochromocytoma Licensing Activities @ Pheochromocytoma Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/pheochromocytoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Contact Us
Yash Bhardwaj
info@delveinsight.com
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pheochromocytoma Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | Pfizer, Exelixis, Ipsen, Genentech, and others. here
News-ID: 3176557 • Views: …
More Releases from DelveInsight Business Research
Global Patient Engagement Solutions Market to reach USD 59,499.28 million by 203 …
According to DelveInsight's analysis, The growth of the patient engagement solutions market is primarily fueled by several major factors, including the increasing burden of chronic conditions such as diabetes and cardiovascular diseases, which require continuous patient involvement and monitoring. The industry is further propelled by the move toward patient-centric healthcare models, ongoing technological innovations, and the introduction of new digital tools and platforms. Moreover, supportive government policies and initiatives aimed…
Global Magnetic Resonance Imaging Devices Market to reach USD 13,553.33 million …
According to DelveInsight's analysis, The growing incidence of chronic illnesses-including heart disease, cancer, and neurological disorders is driving demand for advanced diagnostic methods such as MRI, which provides highly detailed imaging of soft tissues and internal organs. Increasing awareness and a stronger focus on early disease detection are also prompting both patients and healthcare professionals to rely on MRI for faster and more accurate diagnosis. In addition, ongoing technological progress…
Global Microbial Fermentation Technology Market Size was USD 33,956.10 million i …
According to DelveInsight's analysis, The microbial fermentation technology market is experiencing strong growth, largely due to the increasing incidence of chronic illnesses such as cancer and a range of infectious diseases, including HIV, hepatitis B and C, and influenza. The market is also being boosted by the rising need for advanced therapeutic products like cell therapies, monoclonal antibodies, recombinant proteins, and gene therapies. Moreover, progress in synthetic biology and precision…
Global Surgical Robotic System Market to reach USD 29,785.13 million by 2032 at …
According to DelveInsight's analysis, The growing prevalence of chronic illnesses such as cancer, cardiovascular diseases, and orthopedic disorders is driving demand for advanced surgical solutions, which in turn is accelerating the expansion of the surgical robotic systems market. Since many of these conditions require complex, highly precise procedures, robotic-assisted surgery is becoming a preferred option due to its superior precision, less invasive nature, and faster patient recovery. At the same…
More Releases for Pheochromocytoma
Pheochromocytoma Market Emerging Trends and Growth Prospects 2034
Introduction
Pheochromocytoma is a rare tumor arising from adrenal gland chromaffin cells, often associated with excessive catecholamine secretion that leads to hypertension and cardiovascular complications. Although considered an orphan disease due to its rarity, pheochromocytoma has gained increasing medical and research attention over the past decade. Advancements in genetic testing, diagnostic imaging, and molecular therapies have opened new opportunities for more accurate detection and effective management.
The global Pheochromocytoma Market is entering…
Rising Tumor Incidence Rates Fueling Growth In The Pheochromocytoma Market Drivi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
How Large Will the Pheochromocytoma Market Size By 2025?
The market size of pheochromocytoma has been on a steady upward trend over the past years. It is projected to increase from $3.03 billion in 2024 to $3.17 billion in 2025, exhibiting a Compound Annual Growth Rate (CAGR) of 4.7%.…
Emerging Trends Influencing The Growth Of The Pheochromocytoma Market: Innovativ …
The Pheochromocytoma Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Pheochromocytoma Market Size Expected to Be by 2034?
The market size of pheochromocytoma has consistently expanded over the past few years. It's estimated to increase from $3.03 billion in 2024 to $3.17…
Top Factor Driving Pheochromocytoma Market Growth in 2025: Rising Tumor Incidenc …
How Big Is the Pheochromocytoma Market Expected to Be, and What Will Its Growth Rate Be?
The pheochromocytoma market has grown steadily in recent years. It will rise from $3.03 billion in 2024 to $3.17 billion in 2025, at a CAGR of 4.7%. This growth is attributed to increased healthcare spending, a rise in diagnoses and awareness, genetic research, and government initiatives.
The pheochromocytoma market is projected to see steady growth, reaching…
Pheochromocytoma Market Growth, Analysis And Forecast 2033
The new report published by The Business Research Company, titled Pheochromocytoma Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the pheochromocytoma market size has grown steadily in recent years. It will grow from $2.89 billion in 2023 to $3.03…
Pheochromocytoma Market Size, Share, Growth Forecast 2030
Pheochromocytoma, a rare but formidable adrenal gland tumor, has sparked increased interest in the medical community due to its complex nature. This article delves into the competitive landscape, future growth prospects, opportunities, drivers, restraints, and major market players in the Pheochromocytoma market. Additionally, we will explore current market trends and regional insights, shedding light on the evolving landscape of this niche market.
Download Free Pheochromocytoma Market Sample Report Here: (Including Full…
